MDS (Myelodysplastic Syndrome) clinical trials
Showing 251–284 of 284 active trials. Describe your situation to see which ones you may be eligible for.
- Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
- Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
- A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant
- Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
- Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
- Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
- Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT
- A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations
- ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
- A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
- Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia
- The Rationale to Conduct This RWE Study is to Provide Data to Support the Safety of CD34 Selected Grafts Versus T Replete PBSC Transplants to Address Concerns About Increased TRM in CD34 Selected Graft Recipients.
- Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
- Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
- Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)
- A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
- Pathogenesis of Hematologic Malignancies
- Screening for Hematology Branch Protocols
- Biology Studies of Hematologic Cancers
- Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study
- Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
- Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
- Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
- Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
- A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
- A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
- A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
- JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
- Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.